NKTX Nkarta

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.

H.C Wainwright “HCW@Home with Nkarta, Inc.”

July 30, 2025

11:00 a.m. ET – fireside chat

Register for the webcast . A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Nadir Mahmood

Nkarta, Inc.



EN
23/07/2025

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast . A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, , and a replay will be archived on the ...

July 23, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Comp...

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pur...

June 6, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports First Quarter 2025 Financial Results and Corporate High...

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in an April Investor Conference

Nkarta to Participate in an April Investor Conference SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat   A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is...

April 1, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and...

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash b...

March 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch